No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BSX Boston Scientific
- 77.760
- -0.830-1.06%
Close Jul 24 16:00 ET
- 77.960
- +0.200+0.26%
Post 18:23 ET
114.32BMarket Cap63.22P/E (TTM)
78.090High75.410Low15.54MVolume76.600Open78.590Pre Close1.20BTurnover1.06%Turnover Ratio72.67P/E (Static)1.47BShares79.43052wk High5.74P/B113.97BFloat Cap48.35052wk Low--Dividend TTM1.47BShs Float79.430Historical High--Div YieldTTM3.41%Amplitude4.790Historical Low77.275Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Boston Scientific Q2 Adjusted Earnings, Net Sales Rise; Raises 2024 Outlook
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed: Boston Scientific's Strong Performance and Upward Financial Projections
Sector Update: Health Care Stocks Advance in Afternoon Trading
US Stocks Tumble, Magnificent 7 Wipe Out $570 Billion As Mega-Tech Earnings Disappoint, VIX Spikes: What's Driving Markets Wednesday?
Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again
Comments
Morning Movers
Gapping up
$Enphase Energy(ENPH.US$ 's stock went up by 2.3% after the company reported a better-than-expected operating profit for the second quarter, buoyed by renewed demand in the U.S. market.
$Texas Instruments(TXN.US$ stock increased by 1.7% as the semiconductor company reported stronger-than-expected earnings for the second quarter, with adjusted earnings per share that exceeded estimates.
$AT&T(T.US$ ...
Gapping up
$Enphase Energy(ENPH.US$ 's stock went up by 2.3% after the company reported a better-than-expected operating profit for the second quarter, buoyed by renewed demand in the U.S. market.
$Texas Instruments(TXN.US$ stock increased by 1.7% as the semiconductor company reported stronger-than-expected earnings for the second quarter, with adjusted earnings per share that exceeded estimates.
$AT&T(T.US$ ...
Expand 23
1
At the start of the week, around 20% of the S&P 500 companies that had reported their second-quarter earnings, with 80% of them topping expectations, according to FactSet data. $S&P 500 Index(.SPX.US$
Investors have largely priced in the chances of the Federal Reserve cutting interest rates at its September meeting. Combined with rising confidence in a soft landing, the market has continued its rally, with rate-sensitive sectors such as small caps and industrials rising in recent weeks. $Russell 2000 Index(.RUT.US$
...
Investors have largely priced in the chances of the Federal Reserve cutting interest rates at its September meeting. Combined with rising confidence in a soft landing, the market has continued its rally, with rate-sensitive sectors such as small caps and industrials rising in recent weeks. $Russell 2000 Index(.RUT.US$
...
1
The stock price of $Intuitive Surgical(ISRG.US$ , the maker of Da Vinci surgical robot system surged 9.34% after its earnings report on Friday, and its market value exceeded $160 billion.
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
+1
23
1
$Boston Scientific(BSX.US$
Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals
Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals
1
$Boston Scientific(BSX.US$
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
On Paris : Thank you